Document Detail

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
MedLine Citation:
PMID:  23122768     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Patients with homozygous familial hypercholesterolaemia respond inadequately to existing drugs. We aimed to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with this disease.
METHODS: We did a single-arm, open-label, phase 3 study of lomitapide for treatment of patients with homozygous familial hypercholesterolemia. Current lipid lowering therapy was maintained from 6 weeks before baseline through to at least week 26. Lomitapide dose was escalated on the basis of safety and tolerability from 5 mg to a maximum of 60 mg a day. The primary endpoint was mean percent change in levels of LDL cholesterol from baseline to week 26, after which patients remained on lomitapide through to week 78 for safety assessment. Percent change from baseline to week 26 was assessed with a mixed linear model.
FINDINGS: 29 men and women with homozygous familial hypercholesterolaemia, aged 18 years or older, were recruited from 11 centres in four countries (USA, Canada, South Africa, and Italy). 23 of 29 enrolled patients completed both the efficacy phase (26 weeks) and the full study (78 weeks). The median dose of lomitapide was 40 mg a day. LDL cholesterol was reduced by 50% (95% CI -62 to -39) from baseline (mean 8·7 mmol/L [SD 2·9]) to week 26 (4·3 mmol/L [2·5]; p<0·0001). Levels of LDL cholesterol were lower than 2·6 mmol/L in eight patients at 26 weeks. Concentrations of LDL cholesterol remained reduced by 44% (95% CI -57 to -31; p<0·0001) at week 56 and 38% (-52 to -24; p<0·0001) at week 78. Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase levels of more than five times the upper limit of normal, which resolved after dose reduction or temporary interruption of lomitapide. No patient permanently discontinued treatment because of liver abnormalities.
INTERPRETATION: Our study suggests that treatment with lomitapide could be a valuable drug in the management of homozygous familial hypercholesterolaemia.
FUNDING: FDA Office of the Orphan Product Development, Aegerion Pharmaceuticals.
Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader;
Related Documents :
21947148 - Retinal changes in various altitude illnesses.
2757958 - Relapse rates in moderately severe chronic psoriasis treated with cyclosporin a.
138548 - Topical treatment of acne with a tetracycline preparations: results of a multi-group st...
23122768 - Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients...
1555338 - Uncemented total hip arthroplasty in rheumatoid arthritis diseases. a two- to six-year ...
6727528 - Effects of low energy laser on wound healing in a porcine model.
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2012-11-02
Journal Detail:
Title:  Lancet     Volume:  381     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-07     Completed Date:  2013-01-24     Revised Date:  2013-04-09    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  40-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Institute for Translational Medicine and Therapeutics, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Benzimidazoles / adverse effects,  therapeutic use*
Carrier Proteins / antagonists & inhibitors*
Cholesterol, LDL / blood
Hyperlipoproteinemia Type II / blood,  drug therapy*,  genetics
Grant Support
Reg. No./Substance:
0/BMS201038; 0/Benzimidazoles; 0/Carrier Proteins; 0/Cholesterol, LDL; 0/microsomal triglyceride transfer protein
M Cuchel / ; E A Meagher / ; D M Kolansky / ; B S Sachais / ; P K Shah / ; D J Blom / ; A D Marais / ; H du T Theron / ; A M E du Plessis / ; D Gaudet / ; R A Hegele / ; A B Cefalù / ; D Noto / ; M R Averna / ; C R Sirtori / ; A Bondioli / ; M Triolo / ; G Mombelli / ; G B Vigna / ; E Lodi / ; E Menegatti / ; E Tosini / ; C Stefanutti / ; S Di Giacomo /
Comment In:
Lancet. 2013 Apr 6;381(9873):1183   [PMID:  23561998 ]
Lancet. 2013 Apr 6;381(9873):1182   [PMID:  23561997 ]
Lancet. 2013 Jan 5;381(9860):7-8   [PMID:  23122767 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of sewage nutrients on algal production, biomass and pigments in tropical tidal creeks.
Next Document:  Bone mineral density and blood metals in premenopausal women.